Current Therapies to Target HDL - Update on Clinical Trials

Title:

Current Therapies to Target HDL - Update on Clinical Trials

Topic: Cardiology
Relevant Terms: HDL Functionality
Primary Audience: Cardiologists; endocrinologists; internists; lipidologists; primary care physicians; physician assistants; nurse practitioners; pharmacists; registered nurses; and registered dietitians
Launch Date: 28-May-13
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk
  2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families

    Faculty

    Benjamin J. Ansell, MD, FNLA*
    Professor
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA

    Peter H. Jones, MD
    Associate Professor of Medicine
    Section of Atherosclerosis and Lipid Research
    Methodist Debakey Heart and Vascular Center
    Baylor College of Medicine
    Center for Cardiovascular Disease Prevention
    Director, Weight Management Center
    The Methodist Hospital
    Houston, TX
    Laurence S. Sperling, MD, FACC, FAHA, FACP
    The Emory Clinic
    Professor of Medicine
    Medical Director of Preventive Cardiology Clinic
    Atlanta, GA
    Program Overview
    The Translation of HDL Science Curriculum Slide Library consists of 6 (six) interactive slide lecture note modules that convey the latest evidence and research on HDL and residual risk epidemiology, HDL metabolism, HDL functionality and subfractions, existing HDL raising therapies, novel targets of therapy and therapies in development.  The HDL Slide Library provides slide presentation materials with state of the art, peer-reviewed content developed by International experts in lipidology and HDL research.  These slides efficiently translate the core scientific principles of the HDL curriculum to clinical practice.
    Optimizing statin therapy and lifestyle practices should remain the primary focus to altering HDL-C. This slide module will address the current therapies to target HDL through an update on clinical trials. In addition the an overview of how lifestyle changes can positively impact CVD outcomes will be presented.
     
    Activity Format
    Enduring Internet

    Estimated time to complete the activity
    1 hour

    Fee
    There is no fee associated with this activity

    Type of Activity
    Knowledge

    Criteria for Success
    Statements of credit will be awarded based on the participant's successful completion of the post-test with a score of 55% or better and the completion of the activity evaluation form. If you have questions about this CME/CE activity, please contact the NLA at cme@lipid.org. Please claim credit by May 10, 2014.
    For Pharmacists transcript information will be available at www.mycpemonitor.net within 4 weeks.
     
    Commercial Support
    This activity is supported by an unrestricted educational grant from Genentech, USA, Merck & Co., Inc., and Abbott Laboratories.
     
    Credit Designation
    CME credit provided by the National Lipid Association

    Physicians
    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
     
    Physician Assistants
    NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

    CE Credit provided by Postgraduate Institute for Medicine

    Pharmacists

    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-254-H01-P (Knowledge)
    Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
     
    Nursing
    This educational activity for 1 contact hours is provided by Postgraduate Institute for Medicine.
     
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    Dietitians
    This program has been submitted to the Commission on Dietetic Registration (CDR) for 1 CPEUs. Please check back at a later date for approval status.


    Disclosures

    FACULTY/PLANNER FINANCIAL DISCLOSURES
    Name
    Relationship
    Company
    Ansell, Benjamin
    Advisory Board
    Liposcience; Aegerion
    Ownership
    Bruin Pharma
    Stock Holder
    Amgen
    Jones, Peter
    Advisory Board
    Atherotech Diagnostic Lab
    Consultant
    Abbott Laboratories; Merck & Co., Inc.; Roche/Genentech; Daiichi Sankyo, Inc.
    Speakers Bureau
    Abbott Laboratories; AstraZeneca; Merck & Co., Inc.
    Sperling, Laurence
    N/A
    Nothing to disclose

    FACULTY/PLANNER FINANCIAL DISCLOSURES
    Name
    Relationship
    Company

    NLA
    N/A
    Nothing to Disclose
    PIM
    N/A
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     


    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
     
    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac.